Navigating unique challenges and advancing equitable care for children with ADHD in Africa: a review

• Published in: Annals of medicine and surgery 2023-10, Vol.85 (10), p.4939-4946
• Main Authors: Olatunji, Gbolahan, Faturoti, Olamide, Jaiyeoba, Babafemi, Toluwabori, Ayodele V., Adefusi, Temiloluwa, Olaniyi, Peter, Aderinto, Nicholas, Abdulbasit, Muili O.
• Format: Article
• Language: English
• Subjects: Reviews
• ISSN: 2049-0801; 2049-0801
• DOI: 10.1097/MS9.0000000000001179

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that presents distinct challenges for African children due to a complex interplay of social, economic and cultural factors. This review examines the various obstacles faced by children with ADHD in Africa, focusing on the lack of awareness and stigma surrounding the disorder, limited access to mental health services, educational system constraints, economic limitations and cultural beliefs and practices. The review underscores the significance of public awareness campaigns and educational initiatives to dispel myths and misconceptions surrounding ADHD. These efforts should target the general public, educators, healthcare professionals, religious leaders and traditional healers. Crucial to addressing this issue is strengthening mental health services, especially in rural and underserved areas, through increased funding and the availability of trained mental health professionals specialised in ADHD diagnosis and treatment. Integrating mental health services into primary healthcare systems is proposed to enhance accessibility for children with ADHD. By training primary care providers to recognise ADHD symptoms and provide initial support and referrals, early identification and intervention can be facilitated. Addressing the affordability and accessibility of ADHD treatment is a priority, with policy recommendations including subsidising medications and therapies and providing financial assistance to families in need. A call for collaborative efforts between governments, nongovernmental organisations and pharmaceutical companies is advocated to ensure that ADHD treatment is affordable and widely available.